Melanoma is a form of skin cancer that can be successfully managed in the outpatient setting at early stages, but becomes increasingly deadly as the stage of diagnosis increases. Treatment options include targeted therapy and immunotherapy combinations. Checkpoint inhibitors are standard of care for patients without targetable mutations, while patients with BRAF mutations may also receive BRAF/MEK combos. Immuno-oncology agents and novel therapy combinations are likely to emerge as future options and there remains an unmet need for effective treatments following progression on systemic therapy.
Oncology Resource Group (ONCrg) is a team of expert analysts who rigorously evaluate the latest corporate reports, news, and data presentations to distill out important advances in complex therapeutic areas. Our comprehensive medical congress coverage, and continuous market surveillance put these advances into the context of an overarching competitive landscape in melanoma to help guide strategic and tactical commercial development decisions for market participants.
